Xenon Pharmaceuticals Stock Fair Value – XENON PHARMACEUTICALS Reports USD 0.0 Million Revenue in FY2023 Q2 Earnings Results

August 19, 2023

🌥️Earnings Overview

On August 9 2023, XENON PHARMACEUTICALS ($NASDAQ:XENE) reported their FY2023 Q2 earnings results for June 30 2023, revealing a 100.0% decrease in total revenue from the same quarter last year to 0.0 million. Net income also decreased to -47.5 million, a decrease of -31.2 million from the same quarter in the previous year.

Stock Price

On Wednesday, XENON PHARMACEUTICALS reported their earnings results for the second quarter of FY2023, reporting a revenue of USD 0.0 million. Despite this, the stock opened at $35.4 and closed at $35.4, up by 0.3% from the previous day’s closing price of 35.4. This suggests that investors remain confident in the company’s potential.

In recent years, the company has experienced significant growth as it expands its therapeutic pipeline and puts forth new treatments to address unmet medical needs of patients around the world. Going forward, investors can expect XENON PHARMACEUTICALS to continue to report strong financial results from its innovative pipeline of therapies and treatments. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Xenon Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    0.13 -163.68 -125652.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Xenon Pharmaceuticals. More…

    Operations Investing Financing
    -130.77 -173.91 0.7
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Xenon Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    684.9 38.44 10.17
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Xenon Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -83.1% -138065.2%
    FCF Margin ROE ROA
    -103972.0% -17.1% -16.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Xenon Pharmaceuticals Stock Fair Value

    At GoodWhale, our goal is to help investors better understand the wellbeing of companies they may be interested in. We analyzed the wellbeing of XENON PHARMACEUTICALS using our platform and found that the fair value of XENON PHARMACEUTICALS share is around $29.6. This was calculated by our proprietary Valuation Line, which takes into account factors such as risk, growth, and dividends. This means that investors may want to consider whether this stock is overvalued compared to its fair value. We hope that this analysis helps our clients make more informed investment decisions. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The pharmaceutical industry is highly competitive, and Xenon Pharmaceuticals Inc is no exception. As one of the leading companies in the field, Xenon Pharmaceuticals Inc must contend with other top contenders, including Cortexyme Inc, Metacrine Inc, and Syndax Pharmaceuticals Inc. All four companies are competing to develop the most effective treatments for a variety of conditions and diseases. Despite the competition, each company is striving to create the best possible treatments to improve the lives of their patients.

    – Cortexyme Inc ($NASDAQ:MTCR)

    Metacrine Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of metabolic, liver, and gastrointestinal diseases. As of 2022, the company’s market cap stands at 17.45M. Additionally, Metacrine Inc’s Return on Equity (ROE) is -57.69%, which indicates that the company has been unsuccessful in generating profits from its equity investments. The negative ROE indicates that the company’s operational performance is below average.

    – Metacrine Inc ($NASDAQ:SNDX)

    Syndax Pharmaceuticals Inc is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies to improve the lives of patients with cancer. The company has a market cap of 1.64 billion dollars as of 2022, indicating its high value in the market. Its Return on Equity (ROE) of -1.94% is lower than the industry average, which may signify weaker financial performance. Despite this, the company is continuing to focus on developing innovative treatments for cancer patients and has recently approved two new cancer therapies.


    XENON PHARMACEUTICALS reported a significantly lower performance in their FY2023 Q2 earnings results compared to the year prior. Investors should consider the company’s financial standing before investing, as these results have had a negative impact on their future outlook. It may be wise to research the company’s past performance to gain a better understanding of potential risks and rewards when investing in XENON PHARMACEUTICALS.

    Recent Posts

    Leave a Comment